Ipca Laboratories Limited (IPCALAB) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,960 (+1.1% day change)
Key ratios
- P/E ratio
- 43.57
- P/B ratio
- 5.04
- ROE (%)
- 14.15
- ROCE (%)
- 23.17
- Debt/Equity
- 0.1
- Dividend yield (%)
- 0.13
- Market cap (₹ Cr)
- 49,726.03
Forensic checks
Piotroski F-Score: 9/9 · Altman Z-Score: 9.65 · Beneish M-Score: -2.5
InvestSights quality score
74.3/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Revenue: guided 9,000Rs Cr, delivered 8,941.2Rs Cr (FY25) — missed guidance
- Material cost-to-sales improvement: guided 330–340bps, delivered 336bps (9M FY26) — met guidance
Latest earnings call (Q2 FY27)
AI summary: The most important signal was that Ipca sustained margin improvement while domestic pain therapies and export generics delivered broad-based growth despite unusually high logistics and input costs. Consolidated EBITDA margin reached around 22.97%, and management retained FY27 guidance of 14% to 16% overall growth and 22% to 23% consolidated EBITDA margin. The Zerodol-led pain…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.